Loading stock data…
MIRA
$1.04-0.01 (-0.95%)
Market ClosedLast close May 1
MIRA Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MIRA Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.04. The stock is currently near its 52-week low of $0.90, remaining 23.5% below its 200-day moving average. Technical signals show neutral RSI of 51 and bullish MACD crossover, explaining why MIRA maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.04
Potential Upside
5%
Whystock Fair Value$1.09
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican righ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$44.12M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.94
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-72.60%
Volume
Today's trading volume
42,897
Recent News
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Aurora Cannabis Announced Refocused Strategy as Global Medical Sales Hit Record High in 2026 Third Quarter Canopy Growth Reported Mixed Results in its Fiscal Third Quarter of 2026 Cronos Group Launched Premium Lord Jones Brand in Israel in Global Expansion Push Key Takeaways; Psychedelic Sector Clearmind Announced the Inclusion of its […]
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks fell late Thursday afternoon with the NYSE Health Care Index down 0.2% and the He
Top Premarket Gainers
FiEE (MINM) shares were up 37% in recent Thursday premarket activity, after the company said Wednesd
EXCLUSIVE: MIRA Pharmaceuticals' Soon To Be Acquired Weight Loss Drug Reverses Obesity Markers And Cuts Nicotine Craving In Animal Study
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) on Monday revealed new animal study results from SKNY-1, a next-generation oral therapeutic. The company says the findings further support the advancement of SKNY-1 toward Investigational New Drug (IND) enabling studies. With obesity and smoking representing two of the leading causes of preventable death and a combined global market opportunity exceeding $200 billion, MIRA intends to prioritize SKNY-1 as a potential cornerstone asset pending the completio
Psychedelic: Compass, GH Research, MindMed report quarterly earnings
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a patent grant and study results. Q1 EARNINGS: On Thursday, Compass Pathways (CMPS) reported a first quarter loss per share of (24c), which compared to analyst estimates of a loss per share of (49c). The company said cash and cash equivalents were $260.1M as of March 31, compared with $165.1M as of December 31. Compass also guided to full year 2025 net cash used in operatin